Major Estimate Revision • 16h
Consensus revenue estimates increase by 14% The consensus outlook for revenues in fiscal year 2026 has improved. 2026 revenue forecast increased from ₩1.09b to ₩1.25b. EPS estimate increased from ₩20,151 to ₩24,389 per share. Net income forecast to grow 126% next year vs 72% growth forecast for Chemicals industry in South Korea. Consensus price target broadly unchanged at ₩520,909. Share price was steady at ₩330,500 over the past week. Valuation Update With 7 Day Price Move • Jul 29
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩233,500, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 8x in the Chemicals industry in South Korea. Total loss to shareholders of 12% over the past three years. Price Target Changed • Jul 11
Price target increased by 8.1% to ₩497,333 Up from ₩460,000, the current price target is an average from 12 analysts. New target price is 60% above last closing price of ₩311,500. Stock is up 60% over the past year. The company is forecast to post earnings per share of ₩20,239 for next year compared to ₩10,285 last year. Valuation Update With 7 Day Price Move • Jul 07
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩306,500, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 8x in the Chemicals industry in South Korea. Total returns to shareholders of 26% over the past three years. Price Target Changed • Jun 26
Price target increased by 9.7% to ₩473,077 Up from ₩431,154, the current price target is an average from 13 analysts. New target price is 42% above last closing price of ₩333,000. Stock is up 87% over the past year. The company is forecast to post earnings per share of ₩19,974 for next year compared to ₩10,285 last year. Buy Or Sell Opportunity • Jun 16
Now 27% undervalued after recent price drop Over the last 90 days, the stock has fallen 14% to ₩378,500. The fair value is estimated to be ₩518,652, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 24%. Revenue is forecast to grow by 30% in 2 years. Earnings are forecast to grow by 138% in the next 2 years. Valuation Update With 7 Day Price Move • Jun 08
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩324,000, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 9x in the Chemicals industry in South Korea. Total returns to shareholders of 44% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩521,143 per share. Buy Or Sell Opportunity • May 20
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 6.8% to ₩392,000. The fair value is estimated to be ₩494,529, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.7% over the last 3 years. Earnings per share has declined by 24%. For the next 3 years, revenue is forecast to grow by 13% per annum. Earnings are also forecast to grow by 32% per annum over the same time period. Price Target Changed • May 05
Price target increased by 11% to ₩428,846 Up from ₩385,833, the current price target is an average from 13 analysts. New target price is 6.5% below last closing price of ₩458,500. Stock is up 158% over the past year. The company is forecast to post earnings per share of ₩20,528 for next year compared to ₩10,285 last year. Buy Or Sell Opportunity • Apr 30
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 6.2% to ₩458,000. The fair value is estimated to be ₩573,521, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.7% over the last 3 years. Earnings per share has declined by 24%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 32% per annum over the same time period. Reported Earnings • Mar 21
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: EPS: ₩10,285 (down from ₩15,296 in FY 2024). Revenue: ₩923.4b (up 7.0% from FY 2024). Net income: ₩79.1b (down 33% from FY 2024). Profit margin: 8.6% (down from 14% in FY 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 22%. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Mar 11
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₩442,000, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 106% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩419,479 per share. Aankondiging • Mar 11
Soulbrain Co., Ltd., Annual General Meeting, Mar 24, 2026 Soulbrain Co., Ltd., Annual General Meeting, Mar 24, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 52, geumto-ro, sujeong-gu, gyeonggi-do, seongnam South Korea Price Target Changed • Mar 02
Price target increased by 8.9% to ₩365,571 Up from ₩335,667, the current price target is an average from 14 analysts. New target price is 18% below last closing price of ₩445,500. Stock is up 140% over the past year. The company is forecast to post earnings per share of ₩13,194 for next year compared to ₩15,296 last year. Valuation Update With 7 Day Price Move • Feb 06
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₩407,000, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 75% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩490,528 per share. Declared Dividend • Feb 06
Dividend increased to ₩2,350 Dividend of ₩2,350 is 2.2% higher than last year. Ex-date: 30th March 2026 Payment date: 1st January 1970 Dividend yield will be 0.6%, which is lower than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (26% earnings payout ratio) but not covered by cash flows (118% cash payout ratio). The dividend has increased by an average of 3.8% per year over the past 5 years and payments have been stable during that time. EPS is expected to grow by 91% over the next 2 years, which should provide support to the dividend and adequate earnings cover. Aankondiging • Feb 05
Soulbrain Co., Ltd. announces Annual dividend Soulbrain Co., Ltd. announced Annual dividend of KRW 2350.0000 per share, ex-date on March 30, 2026 and record date on March 31, 2026. Price Target Changed • Feb 02
Price target increased by 7.3% to ₩329,333 Up from ₩307,063, the current price target is an average from 15 analysts. New target price is 21% below last closing price of ₩419,500. Stock is up 158% over the past year. The company is forecast to post earnings per share of ₩13,194 for next year compared to ₩15,296 last year. New Risk • Jan 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (7.5% net profit margin). Valuation Update With 7 Day Price Move • Jan 21
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₩339,500, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 47% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩623,091 per share. Valuation Update With 7 Day Price Move • Nov 24
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₩229,500, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 11% over the past three years. Major Estimate Revision • Nov 15
Consensus EPS estimates increase by 14% The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate increased from ₩14,296 to ₩16,301. Revenue forecast steady at ₩922.7m. Net income forecast to grow 92% next year vs 49% growth forecast for Chemicals industry in South Korea. Consensus price target broadly unchanged at ₩289,643. Share price rose 3.5% to ₩268,000 over the past week. Valuation Update With 7 Day Price Move • Sep 12
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩242,000, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 22% over the past three years. New Risk • Aug 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Large one-off items impacting financial results. Major Estimate Revision • Aug 19
Consensus EPS estimates fall by 13% The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate fell from ₩18,980 to ₩16,480 per share. Revenue forecast steady at ₩938.7m. Net income forecast to grow 35% next year vs 35% growth forecast for Chemicals industry in South Korea. Consensus price target broadly unchanged at ₩253,308. Share price fell 2.3% to ₩229,000 over the past week. Valuation Update With 7 Day Price Move • Jul 30
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₩248,500, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 9.7% over the past three years. Valuation Update With 7 Day Price Move • Jul 16
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₩211,500, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 3.3% over the past three years. Aankondiging • Apr 16
Soulbrain Co., Ltd. (KOSDAQ:A357780) announces an Equity Buyback for 86,009 shares, for KRW 15,000 million. Soulbrain Co., Ltd. (KOSDAQ:A357780) announces a share repurchase program. Under the program, the company will repurchase up to 86,009 shares for KRW 15,000 million worth of its shares pursuant to a trust agreement with NH Investment & Securities Co., Ltd. The shares will be repurchased at a price of KRW 174,400 per share. The purpose behind the program is to stabilize the stock price and to enhance shareholder value. The program will continue until October 14, 2025. As of Aril 14, 2025, the company had 22,994 common shares within dividend capacity and had 12,430 shares in treasury through other acquisitions. Valuation Update With 7 Day Price Move • Apr 09
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩161,200, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 8x in the Chemicals industry in South Korea. Total loss to shareholders of 31% over the past three years. Upcoming Dividend • Mar 21
Upcoming dividend of ₩2,300 per share Eligible shareholders must have bought the stock before 28 March 2025. Payment date: 21 April 2025. Payout ratio is a comfortable 11% and this is well supported by cash flows. Trailing yield: 1.0%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (1.7%). Major Estimate Revision • Mar 19
Consensus EPS estimates fall by 11% The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate fell from ₩20,044 to ₩17,886 per share. Revenue forecast steady at ₩901.4m. Net income forecast to grow 9.4% next year vs 26% growth forecast for Chemicals industry in South Korea. Consensus price target broadly unchanged at ₩257,385. Share price was steady at ₩204,500 over the past week. Aankondiging • Mar 11
Soulbrain Co., Ltd., Annual General Meeting, Mar 25, 2025 Soulbrain Co., Ltd., Annual General Meeting, Mar 25, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 34-12, gongdan-gil, chungcheongnam-do, gongju South Korea Valuation Update With 7 Day Price Move • Feb 10
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩188,100, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 8x in the Chemicals industry in South Korea. Total loss to shareholders of 14% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩331,465 per share. Upcoming Dividend • Dec 20
Upcoming dividend of ₩2,000 per share Eligible shareholders must have bought the stock before 27 December 2024. Payment date: 21 April 2025. Payout ratio is a comfortable 11% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (2.2%). Board Change • Dec 09
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Price Target Changed • Nov 16
Price target decreased by 13% to ₩317,692 Down from ₩363,167, the current price target is an average from 13 analysts. New target price is 66% above last closing price of ₩191,300. Stock is down 29% over the past year. The company is forecast to post earnings per share of ₩20,134 for next year compared to ₩16,832 last year. Reported Earnings • Mar 22
Full year 2023 earnings released: EPS: ₩16,832 (vs ₩20,967 in FY 2022) Full year 2023 results: EPS: ₩16,832 (down from ₩20,967 in FY 2022). Revenue: ₩844.0b (down 23% from FY 2022). Net income: ₩130.4b (down 20% from FY 2022). Profit margin: 15% (in line with FY 2022). Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 1% per year. Upcoming Dividend • Dec 20
Upcoming dividend of ₩2,000 per share at 0.7% yield Eligible shareholders must have bought the stock before 27 December 2023. Payment date: 22 April 2024. Payout ratio is a comfortable 12% and this is well supported by cash flows. Trailing yield: 0.7%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (1.8%). Buying Opportunity • Dec 07
Now 20% undervalued Over the last 90 days, the stock is up 31%. The fair value is estimated to be ₩370,680, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 28% in 2 years. Earnings is forecast to grow by 35% in the next 2 years. Major Estimate Revision • Nov 15
Consensus EPS estimates increase by 11%, revenue downgraded The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from ₩892.2m to ₩832.2m. EPS estimate rose from ₩16,585 to ₩18,348. Net income forecast to shrink 0.9% next year vs 46% growth forecast for Chemicals industry in South Korea . Consensus price target broadly unchanged at ₩307,143. Share price rose 11% to ₩270,500 over the past week. Valuation Update With 7 Day Price Move • Jul 17
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩275,500, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 13x in the Chemicals industry in South Korea. Total returns to shareholders of 24% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩280,170 per share. Reported Earnings • Mar 26
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: EPS: ₩20,967 (up from ₩19,124 in FY 2021). Revenue: ₩1.09t (up 6.5% from FY 2021). Net income: ₩162.8b (up 9.6% from FY 2021). Profit margin: 15% (in line with FY 2021). Revenue missed analyst estimates by 1.9%. Earnings per share (EPS) also missed analyst estimates by 11%. Revenue is forecast to grow 6.4% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in South Korea. Major Estimate Revision • Mar 22
Consensus revenue estimates fall by 10% The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from ₩1.17b to ₩1.05b. EPS estimate fell from ₩22,849 to ₩21,841 per share. Net income forecast to shrink 4.3% next year vs 30% growth forecast for Chemicals industry in South Korea . Consensus price target broadly unchanged at ₩291,222. Share price fell 3.9% to ₩210,000 over the past week. Upcoming Dividend • Dec 21
Upcoming dividend of ₩1,950 per share Eligible shareholders must have bought the stock before 28 December 2022. Payment date: 17 April 2023. Payout ratio is a comfortable 8.5% and this is well supported by cash flows. Trailing yield: 0.9%. Lower than top quartile of South Korean dividend payers (3.3%). Lower than average of industry peers (2.4%). Aankondiging • Sep 30
Soulbrain Co., Ltd. (KOSDAQ:A357780) announces an Equity Buyback for KRW 5,000 million worth of its shares. Soulbrain Co., Ltd. (KOSDAQ:A357780) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares pursuant to a trust agreement with Mirae Asset Securities Co., Ltd. The purpose behind the program is to stabilize the stock price and to enhance shareholder value. The program will continue until March 29, 2023. As of September 28, 2022, the company had no common shares within dividend capacity and had 12,430 shares in treasury through other acquisitions. Buying Opportunity • Apr 06
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 9.9%. The fair value is estimated to be ₩296,525, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.9% over the last year. Earnings per share has grown by 17%. Revenue is forecast to grow by 28% in 2 years. Earnings is forecast to grow by 34% in the next 2 years. Buying Opportunity • Mar 07
Now 23% undervalued after recent price drop Over the last 90 days, the stock is down 24%. The fair value is estimated to be ₩276,943, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Upcoming Dividend • Dec 22
Upcoming dividend of ₩1,950 per share Eligible shareholders must have bought the stock before 29 December 2021. Payment date: 18 April 2022. Payout ratio is a comfortable 24% but the company is not cash flow positive. Trailing yield: 0.7%. Lower than top quartile of South Korean dividend payers (2.4%). Lower than average of industry peers (1.4%). Price Target Changed • Dec 08
Price target decreased to ₩356,875 Down from ₩388,571, the current price target is an average from 8 analysts. New target price is 26% above last closing price of ₩282,500. Stock is up 14% over the past year. The company is forecast to post earnings per share of ₩19,614 for next year compared to ₩16,288 last year. Valuation Update With 7 Day Price Move • Nov 24
Investor sentiment improved over the past week After last week's 17% share price gain to ₩273,800, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 9.1% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩261,923 per share. Price Target Changed • Nov 19
Price target decreased to ₩359,286 Down from ₩388,571, the current price target is an average from 7 analysts. New target price is 45% above last closing price of ₩248,100. Stock is up 0.7% over the past year. The company is forecast to post earnings per share of ₩19,824 for next year compared to ₩16,288 last year. Is New 90 Day High Low • Feb 17
New 90-day high: ₩313,600 The company is up 31% from its price of ₩240,000 on 19 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 29% over the same period. Is New 90 Day High Low • Jan 26
New 90-day high: ₩300,000 The company is up 36% from its price of ₩219,800 on 28 October 2020. The South Korean market is also up 36% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it underperformed the Chemicals industry, which is up 43% over the same period. Is New 90 Day High Low • Jan 04
New 90-day high: ₩291,400 The company is up 30% from its price of ₩224,000 on 06 October 2020. The South Korean market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 22% over the same period. Is New 90 Day High Low • Dec 17
New 90-day high: ₩273,800 The company is up 17% from its price of ₩233,100 on 18 September 2020. The South Korean market is up 14% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 20% over the same period. Is New 90 Day High Low • Nov 23
New 90-day high: ₩255,900 The company is up 10.0% from its price of ₩232,000 on 26 August 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 13% over the same period. 
